Immunogenicity of Tumor Organoids derived from colorectal, gastric, gynaecological and non-small cell lung cancer, a Feasibility Study

Recruiting

• Conditions: colorectal cancer/bowel cancer; gastric cancer; non-small cell lung cancer/lung cancer; 10017991

• Registration Number: NL-OMON55942
• Lead Sponsor: ederlands Kanker Instituut

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 150

Inclusion Criteria

i. Patients with colorectal, gastric, gynaecological or non-small cell lung
cancer
ii. Undergoing a tumor biopsy or resection of the primary tumor/metastasis.
With the exception of patients from whom tumor organoids cultures have been
previously derived
iii. Eligible for blood withdrawal of 80cc
iv. Patients must have given written informed consent before any study specific
procedures

Exclusion Criteria

-

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Reactivity of autologous T cells primed with tumor organoids </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-</p><br>